Announcements Trials
Browse Landscape

Phase

Phase 3 5Phase 2 5Phase 1 4Phase 4 1

Status

Completed 4

Sponsor Class

OTHER 4INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Endocrine 3NET 2Genitourinary 1

Conditions

Neuroendocrine Tumors 2Prostatic Neoplasms 1Carcinoid Tumor 1Acromegaly 1

Interventions

pembrolizumab 304Paclitaxel 206Carboplatin 200Gemcitabine 173Cisplatin 139Docetaxel 138Cyclophosphamide 136Nivolumab 129Bevacizumab 118Injections 111fludarabine 96atezolizumab 91Pemetrexed 90Dexamethasone 90Cetuximab 90Fluorouracil 84Irinotecan 77Rituximab 72Capecitabine 72venetoclax 71Azacitidine 70130-nm albumin-bound paclitaxel 67Leucovorin 65Fulvestrant 58Oxaliplatin 57durvalumab 56Trastuzumab 56Lenalidomide 55Ipilimumab 55Midazolam 54

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1 × INDUSTRY × pasireotide × Clear all
NCT00446082 2020-12-21

Study of Pasireotide Long Acting Release (LAR) Injection in Patients With Acromegaly and Patients With Carcinoid Disease

Novartis

Phase 1 Completed
85 enrolled
Endocrine

Acromegaly, Carcinoid Tumor

NCT01364415 2020-12-21

Dose Escalation Study of Pasireotide (SOM230) in Patients With Advanced Neuroendocrine Tumors (NETs)

Novartis

Phase 1 Completed
29 enrolled
EndocrineNET

Neuroendocrine Tumors

NCT01646684 2020-12-21

Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Pasireotide LAR in Patients With Castration Resistant Prostate Cancer

Novartis

Phase 1 Completed
9 enrolled
Genitourinary

Prostatic Neoplasms

NCT01590199 2019-04-16

MACS2002

Novartis

Phase 1 Completed
18 enrolled
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡